

THIEME FLEXIBOOK

Stefan Silbernagl  
Florian Lang

Color Atlas of  
**Pathophysiology**

病理生理学彩色图谱

181 Color Plates by Rüdiger Gay and Astried Rothenburger



 Thieme



CHINA SCIENCE AND TECHNOLOGY PRESS  
中国科学技术出版社

basic sciences

# Color Atlas of Pathophysiology

Stefan Silbernagl

Professor and Head  
Institute of Physiology  
University of Würzburg  
Germany

Florian Lang

Professor  
Institute of Physiology  
1st Department of Physiology  
University of Tübingen  
Germany

Illustrations by  
Rüdiger Gay and  
Astried Rothenburger

This international edition is authorized  
for sale and purchase only in:  
South Asia, Southeast Asia, China,  
and the Middle East & North Africa  
© 2006

2000  
Thieme  
Stuttgart · New York



图书在版编目 (CIP) 数据

病理生理学彩色图谱/ (德) 西尔贝尔纳格尔(Silbernagl, S.), (德) 朗  
(Lang, F.)著. —北京: 中国科学技术出版社, 2006.1

ISBN 7-5046-4219-3

I. 病... II. ①西... ②S... ③朗... ④F... III. 病理生理学—图谱  
IV. R363-64

中国版本图书馆 CIP 数据核字 (2005) 第 135578 号

© 2006 Georg Thieme Verlag, Rüdigerstrasse 14, 70469 Stuttgart, Germany

著作权合同登记号 北京市版权局图字: 01-2005-5207 号

本英文版由德国 Thieme 图书出版公司授权中国科学技术出版社独家出版  
发行, 未经出版者许可不得以任何方式抄袭、复制或节录任何部分

版权所有 侵权必究

策划编辑 肖 叶 单 亭  
责任编辑 周静远  
责任印制 安利平  
法律顾问 宋润君

中国科学技术出版社出版

北京市海淀区中关村南大街 16 号 邮政编码: 100081

<http://www.kjpbooks.com.cn>

电话: 010-62103210 传真: 010-62183872

科学普及出版社发行部发行

北京汇文商业艺术制作有限公司 • 制版

上海盛杰印刷厂印刷

开本: 850×1165 毫米 1/32 印张: 13 字数: 318 千字

2006 年 1 月第 1 版 2006 年 1 月第 1 次印刷

印数: 1—2000 册 定价: 63.00 元

(凡购买本社的图书, 如有缺页、倒页、

脱页者, 本社发行部负责调换)



# Preface

Pathophysiology describes the mechanisms which lead from the primary cause via individual malfunctions to a clinical picture and its possible complications. Knowledge of these mechanisms serves patients when the task is to develop a suitable therapy, alleviate symptoms, and avert imminent resultant damage caused by the disease.

Our aim in writing this *Atlas of Pathophysiology* was to address students of medicine, both prior to and during their clinical training, and also qualified doctors as well as their co-workers in the caring and therapeutic professions and to provide them with a clear overview in words and pictures of the core knowledge of modern pathophysiology and aspects of pathobiochemistry. Readers must themselves be the judge of the extent to which we have achieved this; we would be happy to receive any critical comments and ideas.

The book begins with the fundamentals of the cell mechanism and abnormalities thereof as well as cell division, cell death, tumor growth, and aging. It then covers a wide range of topics, from abnormalities of the heat and energy balance, via the pathomechanisms of diseases of the blood, lungs, kidneys, gastrointestinal tract, heart and circulation, and of the metabolism, including endocrinal abnormalities, diseases of the musculature, the senses, and the peripheral and central nervous system. Following a short review of the fundamentals of physiology, the causes, course, symptoms, and arising complications of disease processes are described along with, if necessary, the possibilities of therapeutic intervention. The selective further reading list will assist the interested reader wishing to gain more indepth knowledge, and a detailed subject index, which is also a list of abbreviations, aims to assist rapid findings of topics and terminology.

This *Atlas* would have been inconceivable without the great commitment and outstanding expertise and professionalism of the graphic designers, Ms. Astried Rothenburger and Mr. Rüdiger Gay. We would like to extend our warmest gratitude to them for their re-

newed productive co-operation. Our thanks also go to our publishers, in particular Dr. Liane Platt-Rohloff, Dr. Clifford Bergman, and Mr. Gert Krüger for their friendly guidance, and Ms. Marianne Mauch for her exceptional skill and enthusiasm in editing the German edition of the *Atlas*. Ms. Annette Ziegler did a wonderful job with the setting, Ms. Koppenhöfer and Ms. Loch sorted and compiled the subject index with great care. Throughout all the years it took for this book to come into being, Dr. Heidi Silbernagl constantly stood by us and offered us her loyal and critical opinion of our pictures and manuscripts.

Several colleagues were likewise very helpful. First and foremost we would like to thank Prof. Niels Birbaumer for his valuable advice concerning the chapter 'Nervous System, Musculature', but we also thank Prof. Michael Gekle, Dr. Erich Gulbins, Dr. Albrecht Lepple-Wienhues, Dr. Carsten Wagner, and Dr. Siegfried Waldegger. Finally, we are grateful to Prof. Eva-Bettina Bröcker, Prof. Andreas Warnke, and Prof. Klaus Wilms for being so kind as to allow us to reproduce their photographs here.

We hope that readers will find in this *Atlas* what they are looking for, that what we have attempted to say in words and pictures is understandable, and that they enjoy using this book throughout their studies and their working life.

Würzburg and Tübingen, Germany  
January 2000

Stefan Silbernagl and Florian Lang

silbernagl@mail.uni-wuerzburg.de  
florian.lang@uni-tuebingen.de



# At a Glance

1	Fundamentals	2
2	Temperature,Energy	20
3	Blood	28
4	Respiration,Acid-Base Balance	66
5	Kidney,Salt and Water Balance	92
6	Stomach,Intestines,Liver	134
7	Heart and Circulation	176
8	Metabolism	242
9	Hormones	256
10	Neuromuscular and Sensory System	298
	Literature	362
	Index	365



# Contents

1

## **Fundamentals** S. Silbernagl and F.Lang

2

- Cell Growth and Cell Adaptation ... 2
- Abnormalities of Intracellular Signal Transmission ... 6
- Necrotic Cell Death ... 10
- Apoptotic Cell Death ... 12
- Development of Tumor Cells ... 14
- Effects of Tumors ... 16
- Aging and Life Expectancy ... 18

2

## **Temperature,Energy** S. Silbernagl

20

- Fever ... 20
- Hyperthermia, Heat Injuries ... 22
- Hypothermia, Cold Injury ... 24
- Obesity, Eating Disorders ... 26

3

## **Blood** S. Silbernagl

28

- Overview ... 28
- Erythrocytes ... 30
- Erythropoiesis, Anemia ... 30
- Erythrocyte Turnover: Abnormalities, Compensation, and Diagnosis ... 32
- Megaloblastic Anemia Due to Abnormalities in DNA Synthesis ... 34
- Anemias Due to Disorders of Hemoglobin Synthesis ... 36
- Iron Deficiency Anemias ... 38
- Hemolytic Anemias ... 40
- Immune Defense ... 42
- Inflammation ... 48
- Hypersensitivity Reactions (Allergies) ... 52
- Autoimmune Diseases ... 56
- Immune Defects ... 58
- Hemostasis and its Disorders ... 60

4

## **Respiration,Acid-Base Balance** F. Lang

66

- Overview ... 66
- Ventilation, Perfusion ... 68
- Diffusion Abnormalities ... 70
- Distribution Abnormalities ... 72
- Restrictive Lung Disease ... 74
- Obstructive Lung Disease ... 76
- Pulmonary Emphysema ... 78
- Pulmonary Edema ... 80
- Pathophysiology of Breathing Regulation ... 82



Hypoxia and Hyperoxia ...	84
Development of Alkalosis ...	86
Development of Acidosis ...	88
Effects of Acidosis and Alkalosis ...	90

5

## **Kidney, Salt and Water Balance** F. Lang

92

Overview ...	92
Abnormalities of Renal Excretion ...	94
Pathophysiology of Renal Transport Processes ...	96
Abnormalities of Urinary Concentration ...	100
Abnormalities of Glomerular Function ...	102
Disorders of Glomerular Permselectivity, Nephrotic Syndrome ...	104
Interstitial Nephritis ...	106
Acute Renal Failure ...	108
Chronic Renal Failure ...	110
Renal Hypertension ...	114
Kidney Disease in Pregnancy ...	116
Hepatorenal Syndrome ...	118
Urolithiasis ...	120
Disorders of Water and Salt Balance ...	122
Abnormalities of Potassium Balance ...	124
Abnormalities of Magnesium Balance ...	126
Abnormalities of Calcium Balance ...	128
Abnormalities of Phosphate Balance ...	130
Pathophysiology of Bone ...	132

6

## **Stomach, Intestines, Liver** S. Silbernagl

134

Function of the Gastrointestinal Tract ...	134
Esophagus ...	136
Nausea and Vomiting ...	140
Gastritis ...	142
Ulcer ...	144
Disorders After Stomach Surgery ...	148
Diarrhea ...	150
Maldigestion and Malabsorption ...	152
Constipation and (Pseudo-)Obstruction ...	156
Acute Pancreatitis ...	158
Chronic Pancreatitis ...	160
Cystic Fibrosis ...	162
Gallstone Disease (Cholelithiasis) ...	164
Jaundice (Icterus) ...	168
Cholestasis ...	168
Portal Hypertension ...	170
Fibrosis and Cirrhosis of the Liver ...	172
Liver Failure ...	174



- Overview ... 176
- Phases of Cardiac Action (Cardiac Cycle) ... 178
- Origin and Spread of Excitation in the Heart ... 180
- The Electrocardiogram (ECG) ... 184
- Abnormalities of Cardiac Rhythm ... 186
- Mitral Stenosis ... 194
- Mitral Regurgitation ... 196
- Aortic Stenosis ... 198
- Aortic Regurgitation ... 200
- Defects of the Tricuspid and Pulmonary Valves ... 202
- Circulatory Shunts ... 202
- Arterial Blood Pressure and its Measurement ... 206
- Hypertension ... 208
- Pulmonary Hypertension ... 214
- Coronary Circulation ... 216
- Coronary Heart Disease ... 218
- Myocardial Infarction ... 220
- Heart Failure ... 224
- Pericardial Diseases ... 228
- Circulatory Shock ... 230
- Edemas ... 234
- Atherosclerosis ... 236
- Nonatherosclerotic Peripheral Vascular Diseases ... 240
- Venous Disease ... 240

- Overview ... 242
- Amino Acids ... 242
- Carbohydrates ... 244
- Lipidoses ... 244
- Abnormalities of Lipoprotein Metabolism ... 246
- Gout ... 250
- Hemochromatosis ... 252
- Wilson's Disease ... 252
- Heme Synthesis, Porphyrrias ... 254

- General Pathophysiology of Hormones ... 256
- Abnormalities of Endocrinal Regulatory Circuit ... 258
- The Antidiuretic Hormone ... 260
- Prolactin ... 260
- Somatotropin ... 262
- Adrenocortical Hormones: Enzyme Defects in Formation ... 264



Adrenocorticoid Hormones: Causes of Abnormal Release ...	266
Excess Adrenocorticoid Hormones: Cushing's Disease ...	268
Deficiency of Adrenocorticoid Hormones: Addison's Disease ...	270
Causes and Effects of Androgen Excess and Deficiency ...	272
Release of Female Sex Hormones ...	274
Effects of Female Sex Hormones ...	276
Intersexuality ...	278
Causes of Hypothyroidism, Hyperthyroidism and Goitre ...	280
Effects and Symptoms of Hyperthyroidism ...	282
Effects and Symptoms of Hypothyroidism ...	284
Causes of Diabetes Mellitus ...	286
Acute Effects of Insulin Deficiency (Diabetes Mellitus) ...	288
Late Complications of Prolonged Hyperglycemia (Diabetes Mellitus) ...	290
Hyperinsulinism, Hypoglycemia ...	292
Histamine, Bradykinin, and Serotonin ...	294
Eicosanoids ...	296

Overview ...	298
Pathophysiology of Nerve Cells ...	300
Demyelination ...	302
Disorders of Neuromuscular Transmission ...	304
Diseases of the Motor Unit and Muscles ...	306
Diagnosis of Motor Unit Diseases ...	308
Lesions of the Descending Motor Tracts ...	310
Diseases of the Basal Ganglia ...	312
Lesions of the Cerebellum ...	316
Abnormalities of the Sensory System ...	318
Pain ...	320
Diseases of the Optical Apparatus of the Eye ...	322
Diseases of the Retina ...	324
Visual Pathway and Processing of Visual Information ...	326
Hearing Impairment ...	328
Disorders of the Autonomic Nervous System ...	332
Lesions of the Hypothalamus ...	334
The Electroencephalogram (EEG) ...	336
Epilepsy ...	338
Sleep Disorders ...	340
Consciousness ...	342
Aphasias ...	344
Disorders of Memory ...	346
Alzheimer's Disease ...	348
Depression ...	350
Schizophrenia ...	352
Dependence, Addiction ...	354
Cerebrospinal Fluid, Blood-Brain Barrier ...	356



Cerebrospinal Fluid Pressure, Cerebral Edema ... 358  
Disorders of Cerebral Blood Flow, Stroke ... 360

Literature

362

Index

365



*For Jakob*

Stefan Silbernagl

---

*For Viktoria and  
Undine, Karl, Philipp, Lisa*

Florian Lang



## Cell Growth and Cell Adaptation

It is more than a hundred years ago that Rudolf Virchow first conceived of his idea of *cellular pathology*, i.e., that disease is a disorder of the physiological life of the **cell**. The cell is the smallest unit of the living organism (Wilhelm Roux), i.e., the cell (and not any smaller entity) is in a position to fulfill the basic functions of the organism, namely *metabolism*, *movement*, *reproduction* and *inheritance*. The three latter processes are made possible only through **cell division**, although cells that can no longer divide can be metabolically active and are in part mobile.

With the exception of the germ cells, whose chromosome set is halved during meiotic division (*meiosis*), most cells divide after the chromosome set has first been replicated, i.e., after mitosis (so-called indirect division of the nucleus) followed by division of the cell (*cytokinesis*). In this process every cell capable of mitosis undergoes a **cell or generation cycle** ( $\rightarrow$  A) in which one mitosis (lasting ca. 0.5–2 h) is always separated from the next one by an **interphase** (lasting 6–36 h, depending on the frequency of division). Most importantly, the cell cycle is governed by certain cycle phase-specific proteins, the cyclins. They form a complex with a protein kinase, called cdc2 or p34<sup>cdc2</sup>, which is expressed during all phases. When cytokinesis is completed (= end of telophase;  $\rightarrow$  A), cells that continually divide (so-called labile cells; see below) enter the **G<sub>1</sub> phase** (gap phase 1), during which they grow to full size, redifferentiate and fulfill their tissue-specific tasks (high ribonucleic acid [RNA] synthesis, then high protein synthesis). This is followed by the **S phase**, which lasts about eight hours. During this phase the chromosome set is doubled (high DNA synthesis). After the subsequent **G<sub>2</sub> phase**, which lasts about one to two hours (high protein and RNA synthesis; energy storage for subsequent mitosis; centriole division with formation of the spindle), the next **mitosis** begins. The *prophase* (dedifferentiation of the cell, e.g., loss of microvilli and Golgi apparatus; chromosomal spiraling) is followed by the *metaphase* (nuclear envelope disappears, chromosomes are in the equatorial plane). Then comes the *anaphase* (chromo-

some division and migration to the poles) followed by the *telophase* (formation of nuclear envelope). Cytokinesis begins in the late stage of the anaphase with development of the cleavage furrow in the cell membrane. After this a new G<sub>1</sub> phase begins.


Cells with a short life-span, so-called **labile cells**, continually go through this cell cycle, thus replacing destroyed cells and keeping the total number of cells constant. Tissues with labile cells include surface epithelia such as those of the skin, oral mucosa, vagina and cervix, epithelium of the salivary glands, gastrointestinal tract, biliary tract, uterus and lower urinary tract as well as the cells in bone marrow. The new cells in most of these tissues originate from division of poorly differentiated stem cells ( $\rightarrow$  p. 28 ff.). One daughter cell (stem cell) usually remains undifferentiated, while the other becomes differentiated into a cell which is no longer capable of dividing, for example, an erythrocyte or granulocyte ( $\rightarrow$  A). Spermatogenesis, for example, is also characterized by such *differentiated cell division*.

The cells of some organs and tissues do not normally proliferate (see below). Such **stable** or **resting cells** enter a resting phase, the **G<sub>0</sub> phase**, after mitosis. Examples of such cells are the parenchymal cells of the liver, kidneys, and pancreas as well as connective tissue and mesenchymal cells (fibroblasts, endothelial cells, chondrocytes and osteocytes, and smooth muscle cells). Special stimuli, triggered by functional demand or the loss of tissue (e.g., unilateral nephrectomy or tubular necrosis; removal or death of portions of the liver) or tissue trauma (e.g., injury to the skin), must occur before these cells re-enter the G<sub>1</sub> phase ( $\rightarrow$  A, B). Normally less than 1% of liver cells divide; the number rises to more than 10% after partial hepatectomy.


The conversion from the G<sub>0</sub> phase to the G<sub>1</sub> phase and, more generally, the trigger for **cell proliferation** requires the binding of growth factors (GFs) and growth-promoting **hormones** (e.g. insulin) to specific receptors that are usually located at the cell surface. However, in the case of steroid receptors these are in the cytoplasm or in the cell nucleus ( $\rightarrow$  C).



## A. Cell Cycle



## B. Compensatory Hyperplasia





The GF receptors are activated (usually tyrosine kinase activity; → p. 7 ff., A 10), which results in *phosphorylation* of a number of proteins. Lastly, the signaling cascade reaches the nucleus, DNA synthesis is stimulated and the cell divides (→ p. 14).

In addition to tissue-specific growth factors (e.g., hepatic growth factor [HGF] in the liver), there are those with a wider spectrum of action, namely epidermal growth factor (EGF), transforming growth factor (TGF- $\alpha$ ), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) as well as certain cytokines such as interleukin 1 and tumor necrosis factor (TNF). **Growth inhibition** (→ p. 14) occurs, for example, in an epithelium in which a gap has been closed by cell division, when neighboring cells come into contact with one another (*contact inhibition*). Even compensatory growth in the liver stops (→ B) when the original organ mass has been regained. TGF- $\beta$  and interferon- $\beta$  are among the signals responsible for this growth regulation.

The regeneration of labile and stable cells does not necessarily mean that the original tissue structure is reconstituted. For this to happen the **extracellular matrix** must be intact, as it serves as the guiding system for the shape, growth, migration, and differentiation of the cell (→ C). The extracellular matrix consists of fibrous structural proteins (collagen I, II–V; elastin) and an intercellular matrix of glycoproteins (e.g., fibronectin and laminin) that are embedded in a gel of proteoglycans and glucosaminoglycans. The extracellular matrix borders on epithelial, endothelial, and smooth muscle cells in the form of *basal lamina* (→ E). Integrins are proteins of the cell membrane that connect the extracellular matrix with the intracellular cytoskeleton and transmit signals for the growth, migration, and differentiation of the cell to the cell interior (→ C). If, as happens in severe tissue damage, the matrix is extensively destroyed (e.g., in a deep gastric ulcer [→ p. 144 ff.] or large skin wound), the original tissue is replaced by *scar tissue*. In this case otherwise resting cells of the connective tissue and mesenchyme also proliferate (see above).

4 When so-called **permanent cells** have died they cannot be replaced, because they are unable to divide. Such cells include, among oth-


ers, nerve cells in adults. The capability of regeneration of an adult's cardiac and skeletal muscle cells is also very limited (→ e.g., myocardial infarction; p. 220).

**Adaptation** to changed physiological or unphysiological demands can be achieved through an increase or decrease in the **number of cells** (*hyperplasia* or *aplasia*; → D, E). This can be triggered by *hormones* (e.g., development of secondary sex characteristics and growth of mammary epithelium during pregnancy) or can serve the process of *compensation*, as in wound healing or after reduction of liver parenchyma (→ B). **Cell size** may either increase (*hypertrophy*), or decrease (*atrophy*) (→ E). This adaptation, too, can be triggered hormonally, or by an increase or decrease in demand. While the uterus grows during pregnancy by both hyperplasia and hypertrophy, skeletal and cardiac muscles can increase their strength only by hypertrophy. Thus, skeletal muscles hypertrophy through training (bodybuilding) or atrophy from disuse (e.g., leg muscle in a plaster cast after fracture or due to loss of innervation). Cardiac hypertrophy develops normally in athletes requiring a high cardiac output (cycling, cross-country skiing), or abnormally, for example, in hypertensives (→ p. 208 ff.). Atrophied cells are not dead; they can be reactivated—with the exception of permanent cells (brain atrophy). However, similar signal pathways lead to atrophy and to “programmed cell death” or apoptosis (→ p. 12), so that an increased number of cells may die in an atrophic tissue (→ D).


**Metaplasia** is a reversible transformation of one mature cell type into another (→ E). This, too, is usually an adaptive course of events. The transitional epithelium of the urinary bladder, for example, undergoes metaplasia to squamous epithelium on being traumatized by kidney stones, and so does esophageal epithelium in reflux esophagitis (→ p. 136 ff.), or ciliated epithelium of the respiratory tract in heavy smokers. The replacement epithelium may better withstand unphysiological demands, but the stimuli that sustain lasting metaplasia can also promote the development of tumor cells (→ p. 14).




C. Regulation of Cell Proliferation, Motility and Differentiation



D. Changes in Cell Population



E. Cell Adaptation





## Abnormalities of Intracellular Signal Transmission

As a rule, hormones do not influence cell functions directly, but via secondary intracellular signals. This signal transmission is disrupted in some diseases and can be influenced by certain drugs and toxins.

Some hormones bind to **receptors of the cell membrane** ( $\rightarrow$  A1–3). Usually through mediation of guanine nucleotide-binding proteins (**G proteins**), the hormone–receptor interaction causes the release of an intracellular **second messenger** which transmits the hormonal signal within the cell. A given hormone can cause different intracellular second messengers to be formed, depending on the target cell and receptor. **Abnormalities** can occur if, for example, the *number of receptors* is reduced (e.g., down-regulation in persistently high hormone concentrations), the receptor's *affinity* for the hormone is reduced, or coupling to the intracellular signaling cascade is impaired ( $\rightarrow$  A; *receptor defects*).

The so-called large, heterotrimeric **G proteins** consist of three subunits, namely  $\alpha$ ,  $\beta$ , and  $\gamma$ . When the hormone binds to the receptor, guanosine 5'-triphosphate (GTP) is bound to the  $\alpha$  subunit in exchange for guanosine 5'-diphosphate (GDP), and the  $\alpha$  subunit is then released from the  $\beta$  subunit. The  $\alpha$  subunit that has been activated in this way is then inactivated by dephosphorylation of GTP to GDP (intrinsic GTPase) and can thus be re-associated with the  $\beta$ - $\gamma$  subunits.

Numerous **peptide hormones** use cyclic adenosine monophosphate (**cAMP**) as second messenger in such a way that, mediated by a *stimulating G protein* ( $G_s$ ), *adenylyl cyclase* (AC) is activated and thus more cAMP is formed ( $\rightarrow$  A1). cAMP activates *protein kinase A* (PKA), which phosphorylates, among others, enzymes and transport molecules. cAMP can also be involved in gene expression via PKA and phosphorylation of a cAMP-responsive element-binding protein (CREB). cAMP is converted to noncyclic AMP by intracellular *phosphodiesterases* and the signal thus turned off. The following hormones act via an **increase in intracellular cAMP concentration**: corticotropin (ACTH), lutotropin (luteinizing hormone [LH]), thyrotropin (TSH), prolactin, somatotropin, some of the liberines (releasing hormones

[RH]) and statins (release-inhibiting hormones [RIH]), glucagon, parathyroid hormone (PTH), calcitonin, adiuretin ([ADH]  $V_2$  receptors), gastrin, secretin, vasoactive intestinal peptide (VIP), oxytocin, adenosine ( $A_2$  receptor), serotonin ( $S_2$  receptor), dopamine ( $D_1$  receptor), histamine ( $H_2$  receptor), and to some extent the prostaglandins.

Some peptide hormones and neurotransmitters, for example, somatostatin, adenosine ( $A_1$  receptor), dopamine ( $D_2$  receptor), serotonin ( $S_{1\alpha}$ ), angiotensin II, and acetylcholine ( $M_2$  receptor), act by inhibiting AC and thus **reducing the intracellular cAMP concentration**, via an *inhibiting G protein* ( $G_i$ ) ( $\rightarrow$  A2). Some hormones can, by binding to different receptors, either increase the cAMP concentration (epinephrine:  $\beta$ -receptor; dopamine:  $D_1$  receptor), or reduce it (epinephrine:  $\alpha_2$ -receptor; dopamine:  $D_2$  receptor).

The cAMP signaling cascade can be influenced by **toxins and drugs**, namely *cholera toxin* from *Vibrio cholerae*, the causative organism of cholera, and other toxins prevent the deactivation of the  $\alpha_s$  subunit. The result is the uncontrolled activation of AC and subsequently of cAMP-dependent  $Cl^-$  channels, so that unrestrained secretion of sodium chloride into the gut lumen causes massive diarrhea ( $\rightarrow$  p.150). Pertussis toxin from *Hemophilus pertussis*, the bacillus that causes whooping-cough (pertussis), blocks the  $G_i$  protein and thus raises, among others, the cAMP concentration (disinhibition of AC). *Forskolin* directly stimulates AC, while *xanthine derivatives*, for example, theophylline, inhibit phosphodiesterase and thus the breakdown of cAMP, which also leads to an increase in cAMP concentration ( $\rightarrow$  A4). The xanthine derivatives are used therapeutically, among other drugs, to cause the bronchial musculature to dilate in asthma by raising the cAMP concentration.

In addition to cAMP, cyclic guanosine monophosphate (**cGMP**) serves as an intracellular messenger ( $\rightarrow$  A5). cGMP is formed by *guanylyl cyclase*. cGMP achieves its effect primarily via activation of a protein kinase G (PKG). Atrial natriuretic factor (ANF) and nitric oxide (NO), among others, also act via cGMP.

Other intracellular transmitters are 1,4,5-



inositol trisphosphate ( $IP_3$ ), 1,3,4,5-inositol tetrakisphosphate ( $IP_4$ ), and diacylglycerol (DAG). A membrane-bound phospholipase C (PLC) splits phosphatidylinositol diphosphate ( $PIP_2$ ) into  $IP_3$  and DAG after being activated by a so-called  $G_0$  protein. This reaction is triggered by, among others, epinephrine ( $\alpha_1$ ), acetylcholine ( $M_1$  receptor), histamine ( $H_1$  receptor), ADH ( $V_1$  receptor), pancreozymin (CCK), angiotensin II, thyrotropin-releasing hormone (TRH), substance P, and serotonin ( $S_1$  receptor).  $IP_3$  releases  $Ca^{2+}$  from intracellular stores. Emptying of the stores opens  $Ca^{2+}$  channels of the cell membrane ( $\rightarrow$  A6).  $Ca^{2+}$  can also enter the cell through ligand-gated  $Ca^{2+}$  channels.  $Ca^{2+}$ , in part bound to calmodulin and through subsequent activation of a calmodulin-dependent kinase (CaM kinase), influences numerous cellular functions, such as epithelial transport, release of hormones, and cell proliferation. DAG stimulates protein kinase C (PKC), which is also activated by  $Ca^{2+}$ . PKC in turn regulates other kinases, transcription factors (see below) and the cytoskeleton. PKC also activates the  $Na^+/H^+$  exchanger leading to cytosolic alkalinization and an increase in cell volume. Numerous cell functions are influenced in this way, among them metabolism,  $K^+$  channel activities, and cell division.

The formation of inositol from inositol monophosphate is inhibited by the antidepressant **lithium** (Li) ( $\rightarrow$  A7). PKC is activated by **phorbol esters** ( $\rightarrow$  A8).

**Arachidonic acid**, a polyunsaturated fatty acid, can be split from membrane lipids, including DAG, by **phospholipase A** ( $\rightarrow$  A9). Arachidonic acid itself has some cellular effects (e.g., on ion channels), but through the action of **cyclo-oxygenase** can also be converted to **prostaglandins** and **thromboxan**, which exert their effect partly by activating adenylyl cyclase and guanylyl cyclase. Arachidonic acid can also be converted to **leukotrienes** by **lipoxygenase**. Prostaglandins and leukotrienes are especially important during inflammation ( $\rightarrow$  p. 48 ff.) and not only serve as intracellular messengers, but also as extracellular mediators ( $\rightarrow$  p. 296). **Lipoxygenase inhibitors** and **cyclo-oxygenase inhibitors**, frequently used therapeutically (e.g., as inhibitors of inflammation and platelet aggregation), inhibit the formation of leukotrienes and prostaglandins.

Insulin and numerous growth factors activate **tyrosine kinases** ( $\rightarrow$  A10), which transmit cellular effects via other kinases, enzymes, and transport proteins. The tyrosine kinases can themselves be part of the receptor, or can attach themselves to the receptor on activation. Kinases frequently act by phosphorylating other kinases and thereby trigger a *kinase cascade*. Thus, the mitogen-activated protein kinase (MAP kinase) is activated by another kinase (MAP kinase kinase). This "snowball effect" results in an avalanche-like increase of the cellular signal. The p-38 kinase and the Jun kinase that regulate gene expression via transcription factors are also activated via such cascades.

Other signaling molecules, such as the *small G proteins* ( $p_{21}$ Ras) or *transcription factors* (e.g., c-Jun, c-Fos, c-Myc,  $NF_{\kappa}B$ , AP-1), are important for signal transduction of growth factors ( $\rightarrow$  p. 14) and in apoptosis ( $\rightarrow$  p. 12).

**Mutations** of the (proto-onco)genes of receptors for growth factors, of tyrosine kinases, of Ras, Jun, or Myc to **oncogenes** can promote autonomous cell proliferation, i.e., the development of *tumor cells* ( $\rightarrow$  p. 14).

Some mediators (e.g., the tumor necrosis factor [TNF] and CD95 [Fas/Apo1] ligand) activate acid sphingomyelinase, which forms *ceramide* from sphingomyelin ( $\rightarrow$  A11). Ceramide triggers a series of cellular effects, such as activation of small G proteins (e.g., Ras), of kinases, phosphatases, and caspases, i.e. proteases which cleave proteins at cystein-aspartate sites. The effects of ceramide are especially important in signal transduction of apoptotic cell death ( $\rightarrow$  p. 12).

**Steroid hormones** (e.g., aldosterone) do not usually act via receptors on the cell membrane, but rather pass easily through the cell membrane due to their solubility in lipids, and then bind to *intracellular (cytosolic or nuclear) receptor proteins* ( $\rightarrow$  A12). The hormone-receptor complex attaches itself to the DNA of the cell nucleus and in this way regulates protein synthesis.